



EXPRESS MAIL NO.: EV 452 775 546 US

Sheet 1 of 5

Application Serial No.: 10/622,618

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

9516-200-999

APPLICATION NO.

10/622,618

APPLICANT

Muller et al.

FILING DATE

July 17, 2003

GROUP

1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
Rb	A01	60/436,975		Muller et al.	—	—	12/30/02
Rb	A02	60/438,448		Muller et al.	—	—	1/7/03
Rb	A03	60/438,450		Muller et al.	—	—	1/7/03
Rb	A04	60/452,460		Muller et al.	—	—	3/5/03
Rb	A05	60/454,149		Man et al.	—	—	3/12/03
Rb	A06	10/316,673		Muller et al.	—	—	12/11/02
Rb	A07	10/748,085		Man et al.	—	—	12/29/03
Rb	A08	10/900,270		Muller et al.	—	—	7/28/04
Rb	A09	10/900,332		Muller et al.	—	—	7/28/04
Rb	A10	10/934,974		Muller et al.	—	—	9/3/04
Rb	A11	2001/056107	12/27/01	Muller et al.	—	—	
Rb	A12	2003/0045726	3/6/03	Muller et al.	—	—	
Rb	A13	2003/0187052	10/2/03	Muller et al.	—	—	
Rb	A14	2004/006096	1/8/04	Muller et al.	—	—	
Rb	A15	2004/0019106	1/29/04	Muller et al.	—	—	
Rb	A16	2004/0147588	7/29/04	Man et al.	—	—	
Rb	A17	2004/0167174	8/26/04	Man et al.	—	—	
Rb	A18	2004/0167199	8/26/04	Muller et al.	—	—	
Rb	A19	2004/0204448	10/14/04	Man et al.	—	—	
Rb	A20	2004/0254214	12/16/04	Muller et al.	—	—	
Rb	A21	2004/0259873	12/23/04	Man et al.	—	—	
	A22	2005/0014727	1/20/05	Muller et al.	—	—	
Rb	A23	3,536,809	10/27/70	Applezweig	—	—	
Rb	A24	3,598,123	8/10/71	Zaffaroni	—	—	
Rb	A25	3,845,770	11/5/74	Theeuwes et al.	—	—	
Rb	A26	3,916,899	11/4/75	Theeuwes et al.	—	—	
Rb	A27	4,008,719	2/22/77	Theeuwes et al.	—	—	
Rb	A28	4,492,708	1/8/85	Spitzer	—	—	
Rb	A29	5,059,595	10/22/91	La Grazie	—	—	
Rb	A30	5,073,543	12/17/91	Marshall et al.	—	—	

Keban Anden

9/7/05

NYJD: 1579147.1

Rb	A31	5,120,548	6/9/92	McClelland et al.	—	—	
Rb	A32	5,354,556	10/11/94	Sparks et al.	—	—	
Rb	A33	5,414,008	5/9/95	Muller et al.	—	—	
Rb	A34	5,463,063	10/31/95	Muller	—	—	
Rb	A35	5,580,888	12/3/96	Warrellow et al.	—	—	
Rb	A36	5,591,767	1/7/97	Mohr et al.	—	—	
Rb	A37	5,605,914	2/25/97	Muller	—	—	
Rb	A38	5,632,984	5/27/97	Wong et al.	—	—	
Rb	A39	5,639,476	6/17/97	Oshlack et al.	—	—	
Rb	A40	5,658,940	8/19/97	Muller et al.	—	—	
Rb	A41	5,674,533	10/7/97	Santus et al.	—	—	
Rb	A42	5,698,579	12/16/97	Muller	—	—	
Rb	A43	5,703,098	12/30/97	Muller	—	—	
Rb	A44	5,728,844	3/17/98	Muller	—	—	
Rb	A45	5,728,845	3/17/98	Muller	—	—	
Rb	A46	5,733,566	3/31/98	Lewis	—	—	
Rb	A47	5,736,570	4/7/98	Muller	—	—	
Rb	A48	5,770,589	6/23/98	Billson	—	—	
Rb	A49	5,801,195	9/1/98	Muller et al.	—	—	
Rb	A50	5,877,200	3/2/99	Muller	—	—	
Rb	A51	5,929,117	7/27/99	Muller et al.	—	—	
Rb	A52	5,968,945	10/19/99	Muller et al.	—	—	
Rb	A53	6,001,368	12/14/99	Jenks	—	—	
Rb	A54	6,011,050	1/4/00	Muller et al.	—	—	
Rb	A55	6,015,803	1/18/00	Wirostko	—	—	
Rb	A56	6,020,358	1/4/00	Muller et al.	—	—	
Rb	A57	6,046,221	4/4/00	Muller et al.	—	—	
Rb	A58	6,075,041	6/13/00	Muller	—	—	
Rb	A59	6,130,226	10/10/00	Muller et al.	—	—	
Rb	A60	6,180,644	1/30/01	Muller et al.	—	—	
Rb	A61	6,200,987	3/13/01	Muller	—	—	
Rb	A62	6,214,857	4/10/01	Muller et al.	—	—	
Rb	A63	6,218,369	4/17/01	Bombardelli et al.	—	—	
Rb	A64	6,225,348	5/1/01	Paulson	—	—	
Rb	A65	6,262,101	7/17/01	Muller et al.	—	—	
Rb	A66	6,284,780	9/4/01	Muller et al.	—	—	
Rb	A67	6,326,388	12/4/01	Man et al.	—	—	
Rb	A68	6,429,221	8/6/02	Muller et al.	—	—	

Karen Anderson 9/7/06

RA	A69	6,479,554	11/12/02	Muller et al.	—	—	
RA	A70	6,518,281	2/11/03	Muller et al.	—	—	
RA	A71	6,656,964	12/2/03	Muller et al.	—	—	
RA	A72	6,699,899	3/2/04	Man et al.	—	—	
RA	A73	6,667,316	12/23/04	Man et al.	—	—	
RA	A74	6,844,359	1/18/05	Muller et al.	—	—	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
RA	B01	EP 0091795	10/19/83	Europe	—	—		
RA	B02	EP 0316594	5/24/89	Europe	—	—		
RA	B03	EP 0 626 957	7/12/94	EP	—	—		
RA	B04	JP 05066591	3/19/93	Japan	—	—		
RA	B05	JP 58188868	11/4/83	Japan	—	—		
RA	B06	WO 95/01348	1/12/95	PCT	—	—		
RA	B07	WO 97/08143	3/6/97	PCT	—	—		
RA	B08	WO 97/23457	7/3/97	PCT	—	—		
RA	B09	WO 98/06692	2/19/98	PCT	—	—		
RA	B10	WO 99/06041	2/11/99	PCT	—	—		
RA	B11	WO 00/01387	1/13/00	PCT	—	—		
RA	B12	WO 01/34606	5/17/01	PCT	—	—		
RA	B13	WO 01/45702	6/28/01	PCT	—	—		
RA	B14	WO 03/080048	10/2/03	PCT	—	—		
RA	B15	WO 03/080049	10/2/03	PCT	—	—		


OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

RA	C01	Bedford et al. 1996, Synthesis of water-soluble prodrugs of the cytotoxic agent combretastatin A4. Bioorganic & Medicinal Chemistry Lett. 6(2):157-160
RA	C02	Chen et al., 2000, Preparation of New Anti-Tubulin Ligands through a Dual-Mode, Addition-Elimination Reaction to a Bromo-Substituted α , β -Unsaturated Sulfoxide. J. Org. Chem. 65:8811-8815
RA	C03	Corral, L.G. et al., 1999, "Immunomodulation by thalidomide and thalidomide analogues," Ann. Rheum. Dis. 58 Suppl 1:1107-113
RA	C04	Cummins et al., 1971, Aust. J. Chem., v. 24(11), pp. 2257-2266
RA	C05	Cushman et al., 1993, Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents. J Med Chem. 35(12):2293-2306
RA	C06	Danion et al., 1972, Tetrahedron, v. 28(15), pp. 4223-4229 (including English language abstract)
RA	C07	Fischer et al., 1993, J. Organomet. Chem., v. 454(1-2), pp. 133-149 (including English language abstract)
RA	C08	Gwaltney et al., 2001, Novel sulfonate analogues of combretastatin A-4: potent antimitotic agents. Bioorg Med Chem Lett. 11(7):871-874

Rebecca Anderson 9/7/08

Rb	C09	Hamel E. 1996, Antimitotic natural products and their interactions with tubulin. Med Res Rev. 16(2):207-231
RA	C10	Hastie SB. 1991, Interactions of colchicine with tubulin. Pharmacol Ther. 51(3):377-401
Rb	C11	Ilg et al., 2001, Organometallics, v. 20(17), pp. 3782-3794
Rb	C12	Laubender et al., 1998, Angewandte Chemie, Int. Ed., v. 37(1/2), pp. 150-152
Rb	C13	Laubender et al., 1999, Chemistry-A European Journal, v. 5(10), pp. 2937-2946
Rb	C14	Li et al., 2002, Synthesis and biological evaluation of 2-indolyloxazolines as a new class of tubulin polymerization inhibitors. Discovery of A-289099 as an orally active antitumor agent. Bioorg Med Chem Lett. 12(3):465-469
Rb	C15	Liou et al., 2002, Synthesis and structure-activity relationship of 2-aminobenzophenone derivatives as antimitotic agents. J Med Chem. 45(12):2556-2562
Rb	C16	Luduena et al., 1991, Tubulin sulfhydryl groups as probes and targets for antimitotic and antimicrotubule agents. Pharmacol Ther. 49(1-2):133-152
Rb	C17	McGown and Fox, 1990, Differential cytotoxicity of combretastatins A1 and A4 in two daunorubicin-resistant P388 cell lines. Cancer Chemother Pharmacol. 26(1):79-81
Rb	C18	Medarde et al., 1999, Synthesis and pharmacological activity of diarylindole derivatives. Cytotoxic agents based on combretastatins. Bioorg Med Chem Lett. 9(16):2303-2308
Rb	C19	Mu et al., 2001, Design, synthesis, and biological evaluation of a series of lavendustin A analogues that inhibit EGFR and Syk tyrosine kinases, as well as tubulin polymerization. J Med Chem. 44(3):441-452
Rb	C20	Nam et al., 2002, Synthesis and anti-tumor activity of novel combretastatins: combretocyclopentenones and related analogues. Bioorg Med Chem Lett. 12(15):1955-1958
Rb	C21	Ohsumi et al., 1998, Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships. J Med Chem. 41(16):3022-3032
Rb	C22	Ohsumi et al., 1998, Syntheses and antitumor activity of cis-restricted combretastatins: 5-membered heterocyclic analogues. Bioorg Med Chem Lett. 8(22):3153-3158
Rb	C23	Pac et al., 1984, J. Org. Chem., v. 49(1), pp. 26-34 (1984)
Rb	C24	Pettit et al., 2002, Antineoplastic agents. 465. Structural modification of resveratrol: sodium resverastatin phosphate. J Med Chem. 45(12):2534-2542
Rb	C25	Pettit et al., 2000, Antineoplastic agents. 443. Synthesis of the cancer cell growth inhibitor hydroxyphenstatin and its sodium diphosphate prodrug. J Med Chem. 43(14):2731-2737
Rb	C26	Pettit et al., 1999, Antineoplastic agents. 410. Asymmetric hydroxylation of trans-combretastatin A-4. J Med Chem. 42(8):1459-1465
Rb	C27	Pettit et al., 1998, Antineoplastic agents. 379. Synthesis of phenstatin phosphate. J Med Chem. 41(10):1688-1695
Rb	C28	Pettit et al., 1989, Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia. 45(2):209-211
Rb	C29	Profitt et al., 1975, A Reagent for the α , β Reduction of Conjugated Nitriles. J. Org. Chem., 40(1), pp. 127-128
Rb	C30	Shirai et al., 1998, Asymmetric synthesis of antimitotic combretadioxolane with potent antitumor activity against multi-drug resistant cells. Bioorg Med Chem Lett. 8(15):1997-2000
Rb	C31	Thorpe PE, 2004, Vascular targeting agents as cancer therapeutics. Clin Cancer Res. 10(2):415-427
Rb	C32	Update on Spindle Poisons - Part II: Vinca Alkaloids and Analogs/Formulations. Future Oncology, Vol. 6 (12):1457-1484 (2002)
Rb	C33	Update on Spindle Poisons - Part III: Novel Agents in Development. Future Oncology, 7 (1/2):1485-1528 (2002)

Reuben Asid 9/17/06

Rb	C34	Verdier-Pinard et al., 1998, Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells. Mol Pharmacol. 53(1):62-76
Rb	C35	Wang et al., 2002, Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation. J Med Chem. 45(8):1697-1711
Rb	C36	Wolff, ed., 1995, <i>Burger's Medicinal Chemistry and Drug Discovery</i> , 5 th ed., pp. 172-178, 949-982
Rb	C37	Yoon et al., 2002, CP248, a derivative of exisulind, causes growth inhibition, mitotic arrest, and abnormalities in microtubule polymerization in glioma cells. Mol Cancer Ther. 1(6):393-404
EXAMINER 		DATE CONSIDERED 9/7/08
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

